NYSE:ABBV - AbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ABBV stock has decreased by 14.4% and is now trading at $72.67. View which stocks have been mosted impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Thursday, April 23rd 2020. View our earnings forecast for AbbVie.

AbbVie Inc (NYSE:ABBV) posted its quarterly earnings data on Friday, February, 7th. The company reported $2.21 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.19 by $0.02. The company earned $8.70 billion during the quarter, compared to the consensus estimate of $8.68 billion. AbbVie had a negative return on equity of 162.54% and a net margin of 23.69%. The firm's quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.90 earnings per share. View AbbVie's earnings history.

AbbVie declared a quarterly dividend on Thursday, February 20th. Shareholders of record on Wednesday, April 15th will be paid a dividend of $1.18 per share on Friday, May 15th. This represents a $4.72 annualized dividend and a yield of 6.50%. The ex-dividend date is Tuesday, April 14th. View AbbVie's dividend history.

AbbVie announced that its board has authorized a stock buyback program on Thursday, December 13th 2018, which permits the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire up to 3.8% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

AbbVie issued an update on its FY20 earnings guidance on Friday, February, 7th. The company provided earnings per share guidance of $9.61-9.71 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.78.

14 equities research analysts have issued 1 year price objectives for AbbVie's shares. Their forecasts range from $78.00 to $105.00. On average, they anticipate AbbVie's stock price to reach $91.83 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price. View analysts' price targets for AbbVie.

News headlines about ABBV stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AbbVie earned a news impact score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and AT&T (T).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (5.86%), State Street Corp (4.65%), FMR LLC (2.72%), Geode Capital Management LLC (1.65%), Norges Bank (1.03%) and Bank of New York Mellon Corp (1.02%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Schroder Investment Management Group, Capital International Investors, Skandinaviska Enskilda Banken AB publ, Victory Capital Management Inc., Levin Easterly Partners LLC, Bank of New York Mellon Corp, and Bank of Montreal Can. View insider buying and selling activity for AbbVie.

ABBV stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Renaissance Technologies LLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, FMR LLC, Nuveen Asset Management LLC, Janus Henderson Group PLC, Farallon Capital Management LLC, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $72.67.

AbbVie has a market capitalization of $107.31 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe. View additional information about AbbVie.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.